J. C. Lee, “Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan”, apjcb, vol. 6, no. 2, pp. 123-132, May 2021.